Skip to main content

When Should QT Prolongation Be Considered in Antiemetic Use?

  • Chapter
  • First Online:
Book cover Gastrointestinal Emergencies

Abstract

Antiemetic medications are commonly prescribed in the acute care setting. Most carry a warning for QTc interval prolongation, which may devolve into potentially fatal arrhythmias. Ondansetron, the most commonly prescribed antiemetic, increases the QTc interval by 6–20 ms, which is not sufficient to cause cardiac arrhythmias in most patients. The risk of significant QTc prolongation after receiving an antiemetic drug is significantly associated with preexisting QTc prolongation, electrolyte abnormalities, and organ failure. Patients who are known to have underlying risk factors should have a screening electrocardiogram performed prior to medication administration. Other patients can safely receive a single dose of an antiemetic without any preceding tests.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cunningham RS. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy. Oncol Nurs Forum. 1997;24(7 Suppl):33–40.

    CAS  PubMed  Google Scholar 

  2. Pourmand A, Mazer-Amirshahi M, Chistov S, et al. Emergency department approach to QTc prolongation. Am J Emerg Med. 2017;35(12):1928–33.

    Article  Google Scholar 

  3. Cohen IT. An overview of the clinical use of ondansetron in preschool age children. Ther Clin Risk Manag. 2007;3(2):333–9.

    Article  CAS  Google Scholar 

  4. Krammes SK, Jacobs T, Clark JM, Lutes RE. Effect of intravenous ondansetron on the QT interval of patients’ electrocardiograms. Pediatr Emerg Care. 2018;34:38–41.

    Article  Google Scholar 

  5. Moffett PM, Cartwright L, Grossart EA, O’Keefe D, Kang CS. Intravenous ondansetron and the QT interval in adult emergency department patients: an observational study. Acad Emerg Med. 2016;23(1):102–5.

    Article  Google Scholar 

  6. Center for Drug Evaluation and Research. Drug Safety and Availability – FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran) [Internet]. U S Food and Drug Administration Home Page. Center for Drug Evaluation and Research; 2012 [cited 26 Oct 2017]; Available from: https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm

  7. Hafermann MJ, Namdar R, Seibold GE, Page RL 2nd. Effect of intravenous ondansetron on QT interval prolongation in patients with cardiovascular disease and additional risk factors for torsades: a prospective, observational study. Drug Healthc Patient Saf. 2011;3:53–8. https://doi.org/10.2147/DHPS.S25623.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Freedman SB, Uleryk E, Rumantir M, Finkelstein Y. Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med. 2014;64(1):19–25.e6.

    Article  Google Scholar 

  9. Trivedi S, Schiltz B, Kanipakam R, Bos JM, Ackerman MJ, Ouellette Y. Effect of ondansetron on QT interval in patients cared for in the PICU. Pediatr Crit Care Med. 2016;17(7):e317–23.

    Article  Google Scholar 

  10. Moeller JR, Gummin DD, Nelson TJ, Drendel AL, Shah BK, Berger S. Risk of ventricular arrhythmias and association with ondansetron. J Pediatr. 2016;179:118–123.e1.

    Article  CAS  Google Scholar 

  11. Goy J-J, Stauffer J-C, Schlaepfer J, Christeler P, editors. Electrolyte disturbances and QT interval abnormalities. In:Electrocardiography (ECG) [Internet]: Bentham Science Publishers; 2013. p. 133–41. [cited 15 Nov 2017]. Available from: http://www.eurekaselect.com/node/112318.

  12. Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28(3):243–9.

    Article  Google Scholar 

  13. Gaffigan ME, Bruner DI, Wason C, Pritchard A, Frumkin K. A randomized controlled trial of intravenous haloperidol vs intravenous metoclopramide for acute migraine therapy in the emergency department. J Emerg Med. 2015;49(3):326–34.

    Article  Google Scholar 

  14. Barni S, Petrelli F, Cabiddu M. Cardiotoxicity of antiemetic drugs in oncology: An overview of the current state of the art. Crit Rev Oncol Hematol. 2016;102:125–34.

    Article  Google Scholar 

  15. Smith HS, Cox LR, Smith BR. Dopamine receptor antagonists. Ann Palliat Med. 2012;1(2). [Internet]. [cited 1 Jan 2012]; Available from: http://apm.amegroups.com/article/view/1039

  16. Malik IA, Khan WA, Qazilbash M, Ata E, Butt A, Khan MA. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995;18(2):170–5.

    Article  CAS  Google Scholar 

  17. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;3(5):479–98.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Efrat Rosenzweig Kean .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kean, E.R., Hinton, M., Roepke, C. (2019). When Should QT Prolongation Be Considered in Antiemetic Use?. In: Graham, A., Carlberg, D.J. (eds) Gastrointestinal Emergencies. Springer, Cham. https://doi.org/10.1007/978-3-319-98343-1_38

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-98343-1_38

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-98342-4

  • Online ISBN: 978-3-319-98343-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics